OVERVIEW | NEWS | MULTIMEDIA | RESEARCH |
Santhera Pharmaceuticals Holding AG Company Summary |
|
|
|
COMPANY DATA |
|||||||||
 |
Homepage | www.santhera.com |
 |
||
Key Developments: Santhera Pharmaceuticals Holding AG
 |
Santhera Pharmaceuticals Holding AG (VTX:SANN) Santhera Presents Preclinical Data On Oral MC4 Receptor Antagonists for Treatment Of Cancer Cachexia At AICR Research Conference NOV 7, 2008 16:03 - Article Views: 771 Santhera Pharmaceuticals Holding AG (VTX:SANN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Pharmaceuticals Holding AG (VTX:SANN) Santhera Raises CHF 15.9 Million In Private Placement With Strategic Investor Ares Life Sciences NOV 6, 2008 16:03 - Article Views: 588 Santhera Pharmaceuticals Holding AG (VTX:SANN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Pharmaceuticals Holding AG (SWF:SANN) Santhera Enrolls Last Patient In Pivotal US Phase III With Snt-mc17/idebenone In Friedreich's Ataxia OCT 31, 2008 17:17 - Article Views: 450 Santhera Pharmaceuticals Holding AG (SWF:SANN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Pharmaceuticals Holding AG (SWF:SANN) Santhera Launches CATENA® In Canada OCT 10, 2008 15:29 - Article Views: 907 Santhera Pharmaceuticals Holding AG (SWF:SANN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Pharmaceuticals Holding AG (SWF:SANN) Publication In European Heart Journal Highlights Potential Of
Santhera's SNT-MC17/idebenone In Duchenne Muscular Dystrophy SEP 25, 2008 15:27 - Article Views: 912 Santhera Pharmaceuticals Holding AG (SWF:SANN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Pharmaceuticals Holding AG (SWF:SANN) Santhera's 2008 Interim Results Reflect Advances In Clinical
Development And Preparation For First Product Launch AUG 22, 2008 15:03 - Article Views: 661 Santhera Pharmaceuticals Holding AG (SWF:SANN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Pharmaceuticals Holding AG (SWF:SANN) Santhera's Omigapil Receives Orphan Drug Designation From FDA And
Emea AUG 15, 2008 15:19 - Article Views: 1,006 Santhera Pharmaceuticals Holding AG (SWF:SANN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Provides Update On Clinical/Regulatory Processes With
Snt-mc17/idebenone For The Treatment Of Friedreich's Ataxia AUG 10, 2008 18:41 - Article Views: 443 Santhera Pharmaceuticals Holding AG (SWF:SANN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera's Ongoing Studies Prevent CHMP Review Under Small Patient
Populations Guideline - Company Expects Negative CHMP Opinion On MAA
for SNT-MC17/Idebenone In Friedreich's Ataxia JULY 25, 2008 03:01 - Article Views: 545 Santhera Pharmaceuticals Holding AG Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- | |
| ||
|
Santhera Receives First Product Approval: Health Canada Approves
Catena® For Treatment Of Friedreich's Ataxia JULY 24, 2008 15:05 - Article Views: 1,711 Santhera Pharmaceuticals Holding AG Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia. Health Canada's decision is the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena®. Santhera has established a wholly owned Canadian subsidiary, Santhera Pharmaceuticals (Canada), Inc. recently incorporated in Montréal, Quebec, to address the needs of Canada's several hundred patients with this rare and severely progressive muscle disease. Launch of Catena is anticipated for the end of October 2008. | |
| ||
467 COMPANY PROFILE VIEWS |
||||
|
|
|
Site Search
| ENGLISH All Languages |
MARKETS |
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
